Visceral Larva Migrans Medication
- Author: Raymond D Pitetti, MD, MPH; Chief Editor: Russell W Steele, MD more...
Medication Summary
Children can be treated with an anthelmintic agent. Severe infections should be treated with systemic corticosteroids.
Anthelmintics
Class Summary
Historically, the treatment of visceral larva migrans (VLM) in adults and children was primarily symptomatic. However, the identification of anthelmintics (eg, thiabendazole, diethylcarbamazine) in the 1960s offered an effective therapeutic choice. Anthelmintics act against the migrating larvae.
Parasite biochemical pathways are different from the human host; thus, toxicity is directed to the parasite, egg, or larvae. The mechanism of action varies within the drug class. Antiparasitic actions may include the following:
- Inhibition of microtubules causes irreversible block of glucose uptake
- Tubulin polymerization inhibition
- Depolarizing neuromuscular blockade
- Cholinesterase inhibition
- Increased cell membrane permeability, resulting in intracellular calcium loss
- Vacuolization of the schistosome tegument
- Increased cell membrane permeability to chloride ions via chloride channels alteration
Mebendazole (Vermox)
Selectively and irreversibly blocks the uptake of glucose and other nutrients in susceptible intestine-dwelling helminths.
Thiabendazole (Mintezol)
Inhibits mitochondrial formate reductase, which is specific for helminth.
Albendazole (Albenza)
Acts primarily by inhibiting tubulin polymerization, resulting in the loss of cytoplasmic microtubules. Tends to be most effective against larval forms.
Gavignet B, Piarroux R, Aubin F, Millon L, Humbert P. Cutaneous manifestations of human toxocariasis. J Am Acad Dermatol. Dec 2008;59(6):1031-42. [Medline].
[Guideline] Grattan CE, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. Dec 2007;157(6):1116-23. [Medline].
Petithory JC. [Visceral and cutaneous larva migrans]. Rev Prat. Nov 30 2007;57(18):1977-83. [Medline].
Lim JH. Toxocariasis of the liver: visceral larva migrans. Abdom Imaging. Mar-Apr 2008;33(2):151-6. [Medline].
Abe K, Shimokawa H, Kubota T, et al. Myocarditis associated with visceral larva migrans due to Toxocara canis. Intern Med. Sep 2002;41(9):706-8. [Medline].
American Academy of Pediatrics. Toxocariasis (visceral larva migrans, ocular larva migrans). In: 1997 Red Book: Report of the Committee on Infectious Diseases. 1997:530-1.
Arango CA. Visceral larva migrans and the hypereosinophilia syndrome. South Med J. Sep 1998;91(9):882-3. [Medline].
Bass JL, Mehta KA, Glickman LT, et al. Asymptomatic toxocariasis in children. A prospective study and treatment trial. Clin Pediatr (Phila). Sep 1987;26(9):441-6. [Medline].
Carvalho EA, Rocha RL. Toxocariasis: visceral larva migrans in children. J Pediatr (Rio J). Mar-Apr 2011;87(2):100-10. [Medline].
Chang S, Lim JH, Choi D, et al. Hepatic visceral larva migrans of Toxocara canis: CT and sonographic findings. AJR Am J Roentgenol. Dec 2006;187(6):W622-9. [Medline].
Chitkara RK, Sarinas PS. Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia. Semin Respir Infect. Jun 1997;12(2):138-48. [Medline].
Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. Apr 2003;16(2):265-72. [Medline].
Dupas B, Barrier J, Barre P. Detection of Toxocara by computed tomography. Br J Radiol. May 1986;59(701):518-9. [Medline].
Feldman GJ, Parker HW. Visceral larva migrans associated with the hypereosinophilic syndrome and the onset of severe asthma. Ann Intern Med. May 15 1992;116(10):838-40. [Medline].
Glickman LT, Magnaval JF. Zoonotic roundworm infections. Infect Dis Clin North Am. Sep 1993;7(3):717-32. [Medline].
Herrmann N, Glickman LT, Schantz PM, et al. Seroprevalence of zoonotic toxocariasis in the United States: 1971-1973. Am J Epidemiol. Nov 1985;122(5):890-6. [Medline].
Inoue K, Inoue Y, Arai T, et al. Chronic eosinophilic pneumonia due to visceral larva migrans. Intern Med. Jun 2002;41(6):478-82. [Medline].
Kabaalioglu A, Ceken K, Alimoglu E, et al. Hepatic toxocariasis: US, CT and MRI findings. Ultraschall Med. Aug 2005;26(4):329-32. [Medline].
Kimmig P, Regnath T, Hassler D. [Toxocariasis: larva migrans visceralis]. Dtsch Med Wochenschr. Dec 10 2004;129(50):2701-2. [Medline].
Kondera-Anasz Z, Kubala A, Mielczarek-Palacz A. [Toxocariasis--a current clinical and diagnostic problem]. Wiad Lek. 2005;58(3-4):218-21. [Medline].
Leone N, Baronio M, Todros L, et al. Hepatic involvement in larva migrans of Toxocara canis: Report of a case withpathological and radiological findings. Dig Liver Dis. Sep 14 2005;[Medline].
Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol. Mar 2001;39(1):1-11. [Medline].
Magnaval JF, Morassin B. Henoch-Schönlein purpura associated with Toxocara canis infection. J Rheumatol. Mar 2000;27(3):818-9. [Medline].
Musso C, Castelo JS, Tsanaclis AM, Pereira FE. Visceral larva migrans granulomas in liver and central nervous system of children who died of bacterial or viral meningitis. Clin Neuropathol. Nov-Dec 2006;25(6):288-90. [Medline].
Obwaller A, Jensen-Jarolim E, Auer H, et al. Toxocara infestations in humans: symptomatic course of toxocarosis correlates significantly with levels of IgE/anti-IgE immune complexes. Parasite Immunol. Jul 1998;20(7):311-7. [Medline].
Overgaauw PA. Aspects of Toxocara epidemiology: human toxocarosis. Crit Rev Microbiol. 1997;23(3):215-31. [Medline].
Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann Trop Med Parasitol. Jan 2010;104(1):3-23. [Medline].
Sarda AK, Kannan R, Sharma DK, et al. Visceral larva migrans. J Postgrad Med. Jul-Sep 1993;39(3):155-7. [Medline].
Sturchler D, Schubarth P, Gualzata M, et al. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol. Oct 1989;83(5):473-8. [Medline].

